"“Help independent media survive. Even $5 keeps us online.”" Currently, a dedicated group— 0.1% of our 2,500 subscribers—generously provides the financial foundation that keeps TheAltWorld accessible to all. We're profoundly grateful to these supporters whose commitment makes our work possible. By joining them as Paypal subscribers, you demonstrate that TheAltWorld efforts matters while strengthening our resolve to resist paywalling our content. Your support today helps us maintain our founding principle: collecting and sharing the best alternative analysis available to everyone, regardless of financial means. Honor the path these early supporters have blazed by becoming a Paypal donnor—together, we can build a sustainable model that respects both our work and our community's diverse economic realities.
Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or RegressionPaul Craig Roberts- After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease st
After just 6 months, 48.4% of #cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization. …………………. TheAltWorld’s Newsletter is free today. But if you enjoyed this post, you can tell TheAltWorld’s Newsletter that their writing is valuable by pledging a future subscription. You won't be charged unless they enable payments.
|
